
浏览全部资源
扫码关注微信
1.广西中医药大学,南宁 530024
2.武警广西总队医院,南宁 530002
3.广西国际壮医医院,南宁 530001
4.广西中医药大学 附属瑞康医院,南宁 530011
韦玉娜,副教授,从事中医经方的实验及临床研究工作,E-mail:18644330@qq.com
韦斌,副主任医师,从事心血管疾病的中西医结合临床研究和实验研究工作,E-mail:120771597@qq.com
收稿日期:2020-11-16,
网络出版日期:2020-12-11,
纸质出版日期:2021-10-05
移动端阅览
韦玉娜,莫雪梅,王强等.黄芪桂枝五物汤合生脉饮治疗糖尿病心肌病心脏功能的临床疗效[J].中国实验方剂学杂志,2021,27(19):104-109.
WEI Yu-na,MO Xue-mei,WANG Qiang,et al.Protective Effect of Huangqi Guizhi Wuwutang Combined with Shengmaiyin on Cardiac Function of Diabetic Cardiomyopathy[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(19):104-109.
韦玉娜,莫雪梅,王强等.黄芪桂枝五物汤合生脉饮治疗糖尿病心肌病心脏功能的临床疗效[J].中国实验方剂学杂志,2021,27(19):104-109. DOI: 10.13422/j.cnki.syfjx.20210334.
WEI Yu-na,MO Xue-mei,WANG Qiang,et al.Protective Effect of Huangqi Guizhi Wuwutang Combined with Shengmaiyin on Cardiac Function of Diabetic Cardiomyopathy[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(19):104-109. DOI: 10.13422/j.cnki.syfjx.20210334.
目的
2
观察黄芪桂枝五物汤合生脉饮治疗糖尿病心肌病心脏功能的疗效及抗心肌纤维化和抗炎作用。
方法
2
将96例患者按随机数字表法分为观察组和对照组各48例。两组均给予控制血糖、血脂、血压及抗心衰等综合措施。对照组口服通脉降糖胶囊,3粒/次,3次/d;观察组口服黄芪桂枝五物汤合生脉饮加减,1剂/d。两组疗程均为3个月。进行治疗前后超声心电图检查记录左室射血分数(LVEF),舒张早期峰值速度E峰/舒张晚期峰值速度A峰,计算(E/A),左心室舒张末期内径(LVEDd)和每搏输出量(SV),检测治疗前后心肌肌钙蛋白-I(cTn-I),cTn-T,肌酸激酶同工酶(CK-MB),乳酸脱氢酶(LDH),转化生长因子-
β
1
(TGF-
β
1
),基质金属蛋白酶-2(MMP-2),胰岛素样生长因子-1(IGF-1),白细胞介素-6(IL-6),IL-1,肿瘤坏死因子-
α
(TNF-
α
),N末端B型利钠肽原(NT-proBNP),可溶性ST2(sST2)和半乳糖凝集素-3(Gal-3)水平;进行治疗前后心功能不全症状评价和中医证候评分。
结果
2
治疗后观察组LVEF,E/A均高于对照组(
P
<
0.01);观察组cTn-I ,cTn-T,LDH和CK-MB水平均低于对照组(
P
<
0.01);观察组TGF-
β
1
,MMP-2,IGF-1,IL-6,IL-1,TNF-
α
,NT-proBNP,sST2和Gal-3水平均低于对照组(
P
<
0.01);观察组临床疗效高于对照组(
Z
=1.974,
P
<
0.05)。
结论
2
在西医常规干预的基础上,黄芪桂枝五物汤合生脉饮加减治疗DCM气阴两虚兼血瘀证患者,具有抗炎、抗心肌纤维化,抑制心肌重塑作用,可起到减轻心肌组织损伤,提高心室舒张功能的效果,从而保护心脏功能,有着较好的临床疗效,值得临床使用。
Objective
2
To observe the protective effect of Huangqi Guizhi Wuwutang combined with Shengmaiyin on the heart function in patients with diabetic cardiomyopathy and explore its anti-myocardial fibrosis and anti-inflammatory effects.
Method
2
The 96 patients were randomly divided into observation group (48 cases) and control group (48 cases). Both groups were given comprehensive measures to control blood sugar, blood lipids, blood pressure and heart failure. Patients in control group took Tongmai Jiangtang capsule, 3 granules/time, 3 times/day. Patients in observation group took Huangqi Guizhi Wuwutang combined with modified Shengmaiyin, 1 dose/day. The treatment courses were three months in both groups. Left ventricular ejection fraction (LVEF), early diastolic peak velocity E peak/late diastolic peak velocity A peak (E/A), left ventricular end diastolic diameter (LVEDd) and cardiac output per stroke (SV) through echocardiography were recorded before and after therapy. Cardiac troponin-I (cTn I), troponin T (cTn-T), creatine kinase isoenzyme -MB (CK-MB), lactate dehydrogenase (LDH), transforming growth factor-
β
1
(TGF-
β
1
) before and after treatment , matrix metalloproteinase-2 (MMP-2), insulin-like growth factor-1 (IGF-1), interleukin-6 (IL-6), IL-1, tumor necrosis factor-
α
(TNF-
α
), N-terminal pro-B-type natriuretic peptide (NT-proBNP), soluble ST2 (sST2) and galectin-3 (Gal-3) levels were detected. Symptom of cardiac insufficiency and traditional Chinese medicine (TCM) syndrome score were evaluated before and after treatment.
Result
2
The LVEF and E/A data in observation group were higher than those in control group (
P
<
0.01). The levels of cTn-I, cTn-T, LDH and CK-MB in the observation group were lower than those in the control group (
P
<
0.01). After treatment, the levels of TGF-
β
1
, MMP-2, IGF-1, IL-6, IL-1, TNF-
α
, NT-proBNP, sST2 and Gal-3 in the observation group decreased and were lower than those in the control group (
P
<
0.01). The clinical efficacy of the observation group was better than that of the control group (
Z
=1.974,
P
<
0.05).
Conclusion
2
On the basis of conventional intervention of western medicine, Huangqi Guizhi Wuwutang combined with modified Shengmaiyin has anti-inflammatory and anti-myocardial fibrosis effects, with inhibitory effect on myocardial remodeling, and can reduce myocardial tissue damage to improve ventricular diastolic function and protect heart function. With such high clinical efficacy, it is worthy of clinical use.
潘利亚 , 张晓卉 , 尹新华 . 糖尿病心肌病发病机制的研究进展 [J]. 中国心血管杂志 , 2017 , 22 ( 2 ): 143 - 146 .
叶加虎 , 孙虹 , 朱平 . 糖尿病心肌病的药物治疗进展 [J]. 中华老年心脑血管病杂志 , 2020 , 22 ( 5 ): 551 - 552 .
张艳 , 王澎澎 , 蔡欢 . 益气养阴活血方治疗早期糖尿病心肌病的临床观察 [J]. 中国中西医结合杂志 , 2017 , 37 ( 5 ): 543 - 546 .
王贞贞 , 赵泉霖 , 宋亚一 , 等 . 中医药防治糖尿病心肌病进展 [J]. 中国中医急症 , 2020 , 29 ( 4 ): 728 - 731 .
张颖 , 关皎 , 刘爽爽 , 等 . 黄芪桂枝五物汤的化学成分和药理作用研究进展 [J]. 吉林医药学院学报 , 2018 , 39 ( 4 ): 295 - 298 .
易丹 . 黄芪桂枝颗粒对糖尿病SD大鼠心肌MAPKs的影响 [D]. 成都 : 成都中医药大学 , 2019 .
林美斯 , 陈哲杰 , 罗林 , 等 . 生脉饮研究现状及其制剂开发中的问题分析 [J]. 中药与临床 , 2017 , 8 ( 2 ): 69 - 73 .
中华医学会糖尿病学分会 . 中国2型糖尿病防治指南(2017年版) [J]. 中华糖尿病杂志 , 2018 , 10 ( 1 ): 4 - 67 .
尹卓娜 , 蔡德鸿 , 陈宏 . 糖尿病性心脏病 [M]. 北京 : 人民军医出版社 , 2004 : 1427 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 233 - 237 .
JIA G , WHALEY-CONNELL A , SOWERS J R . Diabetic cardiomyopathy:a hyperglycaemia- and insulin-resistance-induced heart disease [J]. Diabetologia , 2018 , 61 ( 1 ): 21 - 28 .
董丽 , 杨思进 , 白雪 , 等 . 刍议“消渴病心病”认识糖尿病心肌病 [J]. 天津中医药大学学报 , 2020 , 39 ( 1 ): 117 - 120 .
钟运香 , 袁娇 , 刘丰惠 , 等 . 西洋参化学成分、药理作用及质量控制研究进展 [J]. 中国中医药现代远程教育 , 2020 , 18 ( 7 ): 130 - 133 .
姚红旗 , 侯雅竹 , 王贤良 , 等 . 黄芪心血管药理作用研究进展 [J]. 河南中医 , 2019 , 39 ( 2 ): 302 - 306 .
李昕 , 潘俊娴 , 陈士国 , 等 . 葛根化学成分及药理作用研究进展 [J]. 中国食品学报 , 2017 , 17 ( 9 ): 189 - 195 .
王冰瑶 , 吴晓燕 , 樊官伟 . 丹参素保护心血管系统的药理作用机制研究进展 [J]. 中草药 , 2014 , 45 ( 17 ): 2571 - 2575 .
李曦 , 张丽宏 , 王晓晓 , 等 . 当归化学成分及药理作用研究进展 [J]. 中药材 , 2013 , 36 ( 6 ): 1023 - 1028 .
尹茂山 , 许淑红 , 牟艳玲 . 2型糖尿病大鼠早期血清 cTnI 水平与心功能的变化 [J]. 中国病理生理杂志 , 2015 , 31 ( 9 ): 1709 - 1714 .
高嘉梦 , 胡兵 , 申锷 . 心肌成纤维细胞转分化与糖尿病心肌病的研究进展 [J]. 中华心血管病杂志 , 2020 , 48 ( 10 ): 885 - 889 .
LI G , XING W , ZHANG M , et al . Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats [J]. Am J Physiol Heart Circ Physiol , 2018 , 315 ( 4 ): H802 - H813 .
中华医学会心血管病学分会心力衰竭学组 . 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志 , 2018 , 46 ( 10 ): 760 - 789 .
SHAH R V , JANUZZI J R . Soluble ST2 and galectin-3 in heart failure [J]. Clin Lab Med , 2014 , 34 ( 1 ): 87 - 97 .
0
浏览量
24
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621